Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

BACKGROUND: The number of obese people continues to increase worldwide, and obesity-related complications add to every country’s health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ying, Zheng, Shui-Lian, Ye, Xiao-Lan, Shi, Jia-Na, Zheng, Xiao-Wei, Pan, Han-Sheng, Zhang, Yi-Wen, Yang, Xiu-Li, Huang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904982/
https://www.ncbi.nlm.nih.gov/pubmed/35284548
http://dx.doi.org/10.21037/atm-22-200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904982/
https://www.ncbi.nlm.nih.gov/pubmed/35284548
http://dx.doi.org/10.21037/atm-22-200

Ejemplares similares